Adverse Events of Lutetium-177-PSMA-617 Revealed
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine